A Team That Pushes Boundaries
To fully integrate cancer research and care, xCures assembled an experienced, boundary-pushing team with the expertise, creativity, and persistence needed to solve the biggest problems in oncology.
Management
Chief Technology Officer
Chief Technology Officer
Glenn Kramer has developed AI-enhanced computational geometry engines, transaction processing systems, business intelligence / market monitoring systems, and innovative investment products that use predictive analytics. He holds 22 issued US Patents. He was most recently Chief Data Scientist at SRS Acquiom. He holds BS and MS degrees in Electrical Engineering and Computer Science from MIT, and a PhD in Artificial Intelligence from the University of Sussex.
Chief Product Officer
Chief Product Officer
Kenny has over a decade of product leadership/management experience in growing innovative healthcare products. Most recently, he was the Vice President of Products at GenomeSmart which was acquired by Ambry Genetics in 2020, a subsidiary of Konica Minolta. Prior to that, he was the Senior Product Director for Counsyl, which was acquired by Myriad Genetics in 2018. Kenny developed his passion for helping patients early in his career as a board-certified genetic counselor at UCSF Medical Center. He holds a BSc from University of British Columbia in Cell Biology and Genetics and a MS in Human Genetics from Sarah Lawrence College.
Chief Executive Officer
Chief Executive Officer
Mika Newton has over twenty years of leadership experience in the life sciences. Most recently he was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.
Chief Operating Officer
Chief Operating Officer
Mark Shapiro is a pharmacologist and widely recognized expert on growth and innovation strategies in clinical research and clinical development. As a management consultant at Campbell Alliance, he led strategic planning, growth, and change management initiatives at many pharmaceutical, biotech and clinical research organizations. He was most recently the SVP, Operations at Clinipace, a global, oncology-focused CRO, where he was part of the leadership team that grew the organization from ten to over a thousand employees worldwide.
Chief Medical Officer (Consulting)
Chief Medical Officer (Consulting)
Dr. Santosh Kesari is a board-certified neurologist, neuroscientist and neuro-oncologist. He is currently Chair and Professor, Department of Translational Neurosciences, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence St. John’s Health Center in Santa Monica. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd. He is a winner of an Innovation Award by the San Diego Business Journal and GBM Heroes Award. He is on the advisory board of the The Brain Observatory, American Brain Tumor Association, End Brain Cancer, San Diego Brain Tumor Foundation, CureScience Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance as well as numerous biotechnology companies. He has been the author of over 300 scientific publications, reviews, or books.
Team
Principal Software Engineer
Brain Cancer Subject Matter Expert & Business Dev.
Clinical Data Associate
Clinical Data Associate
Clinical Data Associate
Lead Data Scientist, Precision Medicine
VP of Engineering
VP of Clinical Operations
Director of Program Management
Informatics Architect
Director of Informatics
Business Development Associate
Graphic Design & Social Media Director
Clinical Data Associate
Senior Data Scientist
Principal Software Engineer
Director, Precision Medicine
Sr. Software Engineer
VP, Research Partnerships
VP Marketing
Assistant to Mika Newton
Clinical Data Associate
Registered Nurse, Clinical Research Coordinator
Clinical Data Manager
Clinical Data Associate
VP of Scientific and Medical Affairs
Clinical Data Manager
Director of Product Management
Founders
Co-Founder & Director Of Research
Co-Founder & Director Of Research
Jeff Shrager, PhD, has over 20 years of experience in applying high performance cloud computing and machine learning in biological science. After an AI/machine learning PhD at CMU, Dr. Shrager worked for a decade at Xerox PARC. Following that, he co-founded a successful computational drug discovery company, and then spent a decade doing wet lab biology, and developing a cloud-based platform for intelligent molecular biocomputing. In the last decade, Jeff co-founded another genomic startup, and then joined SRI International’s biological AI-group and Cancer Commons. As an xCures co-founder, Jeff is responsible for envisioning and developing both the high level and low level AI and machine learning aspects of the virtual trial and virtual tumor board products.
Co-Founder And Chairman
Co-Founder And Chairman
Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006), and Medstory (sold to Microsoft in 2007). Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former Director of Patients Like Me. Dr. Tenenbaum holds BS and MS degrees in Electrical Engineering from MIT, and a PhD from Stanford, and has received numerous awards for his work in AI and as a patient advocate.
Board of Directors
Fei received her Ph.D. in Neuropharmacology from Loyola University Chicago Stritch School of Medicine and a B.Sc in Biochemistry from East China University Science & Technology. In 2007, she started her industrial career at Theravance Biopharma as an in vivo pharmacologist and led a lab in driving multiple research projects from exploratory, lead optimization to development candidate nomination. In 2015, she joined Boehringer Ingelheim Pharmaceuticals Inc. Global Immunology and Respiratory Disease Research in Ridgefield where she started as a Laboratory Head and became the Head of in vivo Pharmacology group in 2016. In 2020, she joined the Boehringer Ingelheim Venture Fund USA as an Investment Director, and was promoted to be the Managing Director in 2021 and leads the US activities.
Katie Chudnovsky is the general counsel for a national privately-held technology firm. She also has her hands in numerous other projects, investing and providing support for a telehealth start-up, a private healthcare organization and a helicopter airport. Chudnovsky is passionate about philanthropy, and in addition to providing major donations to a number of universities and research hospitals she is also president of the board of directors for a large non-profit.
Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton is an Emeritus Member of the Board of Trustees of the American Association for Cancer Research Foundation and is on the Board of Directors of Cancer Commons. In the for-profit sector, he serves on the Boards of Directors of Cellsonics, Matternet, Microsonic Systems, Nanotics, Omniox (also serving as Executive Chair), RenovoRx, and xCures and is an advisor to Assurance Health Data, PharmaJet, and the Precision Medicine World Conference.
Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine.
Chairman
Chairman
Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006), and Medstory (sold to Microsoft in 2007). Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former Director of Patients Like Me. Dr. Tenenbaum holds BS and MS degrees in Electrical Engineering from MIT, and a PhD from Stanford, and has received numerous awards for his work in AI and as a patient advocate.
Chief Executive Officer
Chief Executive Officer
Mika Newton has over twenty years of leadership experience in the life sciences. Most recently he was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.
Moe Kermani is a Managing Partner of Vanedge Capital where he focuses on investments in Cloud computing, Artificial Intelligence, Cybersecurity, Analytics, and Quantum Information. Prior to that he was President and CEO of Bycast Inc., a world leader in object storage that was successfully acquired by NetApp. Moe has extensive experience working with entrepreneurial companies and taking to market leading-edge technology products. He holds a PhD in physics from the University of British Columbia.
Scientific Advisory Board
Chairman
Chairman
Keith Flaherty is a Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Massachusetts General Hospital Cancer Center, where he was named as the Richard Saltonstall Endowed Chair in Oncology.
Jennifer R. Grandis is the Robert K. Werbe Distinguished Professor in the Department of Otolaryngology for Head and Neck Surgery at the University of California, San Francisco. Dr. Grandis’s research focuses on signal transduction in head and neck squamous cell carcinoma (HNSCC) development and progression. She is an American Cancer Society Clinical Research Professor.
Steven D. Averbuch, M.D. is a medical oncologist and pharmaceutical industry veteran with more than 35 years in oncology drug development and more than a decade in biomarker and drug diagnostic co-development.
Advisory Board
Craig Lipset is a recognized leader at the forefront of innovation in clinical research and medicine development. The past Head of Clinical Innovation and Venture Partner at Pfizer, he is currently an advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement.
David Hartford has more than 40 years of experience in the U.S. and Europe as a private equity investor, venture capitalist, and entrepreneur. During his career, he has also undertaken direct C-suite roles and been a practicing securities attorney. He was a founding partner of Calibrium AG (formerly known as Aeris Capital) and now is a senior advisor to the firm.
Elizabeth Hutt Pollard is currently the Executive Chair of Applied Silver, Inc. a privately held company addressing infection prevention in the health, athletic and consumer markets. She is a C-Suite veteran and has extensive experience bringing to market highly specialized technology and solutions for healthcare. She currently serves as a strategic advisor to several early-stage life science companies. She is the Global Board Director at YPO, the premier leadership organization of chief executives in the world, and the Secretary of Science and Innovation for OK.
Josh Tenenbaum is a professor of Computational and Cognitive Science at the Massachusetts Institute of Technology, and a MacArthur Fellow. His research focus at the Computational Cognitive Science group is to understand that most elusive aspect of human intelligence: our ability to learn so much about the world, so rapidly and flexibly. While the group’s core focus is on human learning and reasoning, they also work actively in machine learning and artificial intelligence.
Rob Rodin is the Chairman and CEO of RDN Group and a strategic investor/advisor and manager, focusing on portfolio companies for several venture capital and private equity funds. He served for more than 10 years as CEO and President of Marshall Industries where he engineered the reinvention of the company, turning a conventionally successful $500 million distributor into a web-enabled $2 billion global competitor.
Medical Advisors
Baton Rouge General Hospital - Chief of Oncology Services
Baton Rouge General Hospital - Chief of Oncology Services
Dr. Sanjay Juneja is a triple board-certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, and a Founding Medical Partner of Doctorpedia.com where he serves as Chief Medical Officer of the Oncology Channel.
Massachusetts General Hospital, Gastrointestinal Cancers
Massachusetts General Hospital, Gastrointestinal Cancers
Dr. Parikh is a GI oncologist with expertise in liquid biopsies and clinical trials. She also serves on the NCCN guidelines for colorectal cancer and serves on the NCI Colorectal and Pancreatic Task Forces. She is an active member of ASCO and among other roles with ASCO, a proud member of the Education Council. Most importantly, she is a patient advocate working towards a better tomorrow for our patients not only locally but globally.
NYU - Bladder Cancer
NYU - Bladder Cancer
Gary Steinberg, MD, Professor Department of Urology and the Perlmutter Cancer Center NYU Langone Health and Director Goldstein Urology Program in Bladder Cancer specializes in urologic oncology. He has been instrumental in developing innovative surgical procedures for patients with bladder cancers.
University of Alabama, Birmingham - Neuro-oncology
University of Alabama, Birmingham - Neuro-oncology
L. Burt Nabors, MD, received his M.D. degree from the University of Tennessee in Memphis in 1991 and interned at the National Naval Medical Center. He completed a residency in Neurology at UAB in 1998 and a fellowship in Neuro-oncology in 1999 under the direction of Dr. Steven S. Rosenfeld. He joined the Neuro-Oncology Program in 1999 as an Assistant Professor of Neurology and assumed the position of Program Leader in 2005. He is board-certified in Neurology and holds medical licensure in Alabama. Currently Dr. Nabors is Professor and Vice-Chair of Neurology and Neurosurgery for Research at the University of Alabama at Birmingham. He serves as the Medical Director of the Clinical Research Unit of the Center for Clinical and Translational Science and Co-leader of the O’Neal Comprehensive Cancer Center Neuro-oncology Program. He maintains active basic, translational, and clinical research efforts. His laboratory is examining the role of RNA-binding proteins in neurological disease particularly cancer with an emphasis on therapeutic development.
Sharp Healthcare - Advanced Cancer
Sharp Healthcare - Advanced Cancer
Dr. Charles Redfern is the Medical Director of Medical Oncology for the Laurel Amtower Cancer Institute and Neuro-Oncology Center, a part of Sharp Healthcare in San Diego -
Cedars-Sinai Medical Center - Sarcoma, Advanced Cancer, Oncology Drug Development
Cedars-Sinai Medical Center - Sarcoma, Advanced Cancer, Oncology Drug Development
Cedars-Sinai, Los Angeles
Duke University - Prostate Cancer, Bladder Cancer
Duke University - Prostate Cancer, Bladder Cancer
Dr Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 200 peer-reviewed publications.
Columbia University - Neuro-oncology
Columbia University - Neuro-oncology
Dr. Iwamoto is a neuro-oncologist and the deputy director of Neuro-oncology at Columbia University Irving Medical Center. His research interests are focused on brain tumors, specifically glioblastoma in the aging population, and immunotherapies for gliomas. He recently published in Nature Medicine and Nature Cancer on potential predictors of response to PD-1 inhibitors in glioblastomas and is expanding such analysis to other gliomas. He has filed two patent applications on potential predictive biomarkers for response to PD-1 inhibitors in glioblastomas. He has been the principal investigator of multiple clinical trials and has led national studies in gliomas and glioblastomas.
Pacific Neuroscience Institute and Saint John's Cancer Institute - Neuro-oncology, Advanced Cancer
Pacific Neuroscience Institute and Saint John's Cancer Institute - Neuro-oncology, Advanced Cancer
Dr. Santosh Kesari is a board-certified neurologist, neuroscientist and neuro-oncologist. He is currently Chair and Professor, Department of Translational Neurosciences, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence St. John’s Health Center in Santa Monica. Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd. He is a winner of an Innovation Award by the San Diego Business Journal and GBM Heroes Award. He is on the advisory board of the The Brain Observatory, American Brain Tumor Association, End Brain Cancer, San Diego Brain Tumor Foundation, CureScience Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance as well as numerous biotechnology companies. He has been the author of over 300 scientific publications, reviews, or books.
Investors
